Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 109–120 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

NCT06484114
View directory record Official record
Conditions
Obesity, Weight Change Trajectory, Weight Change, Body
Interventions
Revita Duodenal Mucosal Resurfacing (DMR), Sham
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

NCT07095517
View directory record Official record
Conditions
Colorectal Cancer Prevention, Colorectal Adenoma
Interventions
Tirzepatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

NCT06914141
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
28,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Completed Phase 1 Interventional

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

NCT06916065
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide and Tirzepatide, Eloralintide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Completed No phase listed Observational

Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data

NCT06914154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
11,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Apitegromab, Placebo, Tirzepatide
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT06518837
View directory record Official record
Conditions
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081
View directory record Official record
Conditions
Atrial Fibrillation, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 20, 2026, 3:19 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.